Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: JERSEY

Sector: Medical Instruments and Supplies

Novocure Limited is an oncology company. The Company researches and develops novel technologies for the treatment of cancer. Novocure serves the healthcare industry worldwide.
Website: novocure.com


  • Pretty weak financial results growth rate 4.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (3.7%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -4.7% (LTM)
  • Share price is 36.1% higher than minimum and 55.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $0.9 mln (-0.052% of cap.)

Key Financials (Download financials)

Ticker: NVCR
Share price, USD:  (-2.6%)14.84
year average price 13.74  


year start price 11.32 2025-08-02

min close price 10.90 2025-08-11

max close price 19.99 2026-07-23

current price 14.84 2026-08-01
Common stocks: 104 660 476

Dividend Yield:  0.0%
EV / Sales: 2.0x
Margin (EBITDA LTM / Revenue): -22.7%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 1 553
Net Debt ($m): -211
EV (Enterprise Value): 1 342
EBITDA LTM (млн $): -149
Price to Book: 4.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-02seekingalpha.com

NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative Buy

2025-09-10seekingalpha.com

NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

2025-08-22zacks.com

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

2025-07-30seekingalpha.com

NovoCure's Wearable Oncology Edge And Compelling Valuation

2025-07-25seekingalpha.com

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

2025-06-30zacks.com

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

2025-06-18zacks.com

What Makes NovoCure (NVCR) a New Buy Stock

2025-06-06zacks.com

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

2025-05-31businesswire.com

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

2025-05-24seekingalpha.com

NovoCure: Loading Up On Growth Catalysts
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-30 2025-07-24 2024-10-30 2024-07-25 2024-05-02 2023-10-26 2023-07-27 2023-05-04 2022-10-27
acceptedDate 2025-10-30 07:00:11 2025-07-24 07:01:32 2025-02-27 07:01:11 2024-10-30 07:00:29 2024-07-25 07:05:37 2024-05-02 07:01:24 2024-02-22 07:05:37 2023-10-26 07:02:57 2023-07-27 07:02:15 2023-05-04 07:02:04 2023-02-23 07:05:47 2022-10-27 07:19:41 2022-02-24 06:57:10 2021-02-25 06:27:46
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 167M 159M 605M 155M 150M 139M 509M 127M 126M 122M 538M 131M 535M 494M
costOfRevenue 45M 41M 137M 35M 35M 34M 128M 32M 34M 30M 115M 30M 115M 107M
grossProfit 122M 117M 468M 120M 116M 105M 381M 95M 92M 93M 423M 101M 420M 388M
grossProfitRatio 0.732 0.739 0.772 0.77 0.757 0.748 0.73 0.758 0.773
researchAndDevelopmentExpenses 54M 56M 210M 52M 55M 52M 223M 54M 55M 60M 206M 52M 201M 132M
generalAndAdministrativeExpenses 46M 44M 190M 40M 38M 40M 164M 42M 41M 42M 133M 33M 126M 107M
sellingAndMarketingExpenses 59M 57M 239M 60M 57M 55M 227M 58M 58M 51M 174M 41M 137M 118M
sellingGeneralAndAdministrativeExpenses 104M 101M 429M 100M 94M 95M 391M 100M 99M 93M 306M 74M 263M 225M
otherExpenses 0 0 0 0 -27 000 0 0 0 0 0 0 0 0 0
operatingExpenses 158M 157M 639M 152M 149M 146M 615M 153M 155M 153M 512M 126M 464M 357M
costAndExpenses 203M 198M 776M 187M 184M 180M 742M 186M 189M 182M 627M 156M 579M 464M
interestIncome 6M 5M 51M 0 0 0 46M 10M 0 0 16M 0 1M 6M
interestExpense 0 0 12M 0 0 0 5M 0 0 -9M 8M 1M 9M 18M
depreciationAndAmortization 4M 3M 11M 2M 3M 3M 11M 3M 3M 3M 11M 3M 10M 9M
ebitda -26M -36M -110M -30M -31M -39M -177M -55M -60M -60M -68M -22M -38M 45M
ebitdaratio -0.158 -0.227 -0.191 -0.205 -0.279 -0.435 -0.476 -0.493 -0.168
operatingIncome -36M -40M -170M -32M -34M -42M -233M -58M -63M -60M -90M -25M -44M 30M
operatingIncomeRatio -0.215 -0.249 -0.207 -0.224 -0.3 -0.457 -0.497 -0.493 -0.188
totalOtherIncomeExpensesNet 6M 5M 39M 11M 11M 10M 41M 10M 9M 9M 8M 1M -8M -12M
incomeBeforeTax -30M -35M -131M -22M -23M -32M -192M -48M -54M -51M -82M -23M -52M 18M
incomeBeforeTaxRatio -0.18 -0.22 -0.139 -0.151 -0.228 -0.379 -0.428 -0.418 -0.179
incomeTaxExpense 7M 5M 37M 9M 11M 7M 15M 1M 4M 2M 11M 3M 6M -2M
netIncome -37M -40M -169M -31M -33M -39M -207M -49M -57M -53M -93M -27M -58M 20M
netIncomeRatio -0.223 -0.253 -0.197 -0.222 -0.28 -0.389 -0.456 -0.434 -0.203
eps -0.33 -0.36 -1.56 -0.28 -0.31 -0.36 -1.95 -0.46 -0.54 -0.5 -0.88 -0.25 -0.56 0.2
epsdiluted -0.33 -0.36 -0.28 -0.31 -0.36 -0.46 -0.54 -0.5 -0.25
weightedAverageShsOut 112M 112M 108M 108M 108M 107M 106M 107M 106M 106M 105M 105M 103M 101M
weightedAverageShsOutDil 112M 112M 108M 108M 108M 107M 106M 107M 106M 106M 105M 105M 103M 109M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-22 2023-02-23 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 39M 41M 8M -8M -12M
ebit -121M -188M -79M -49M 36M
nonOperatingIncomeExcludingInterest -50M -44M -11M 4M -5M
netIncomeFromContinuingOperations -169M -207M -93M -58M 20M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -169M -207M -93M -58M 20M
epsDiluted -1.56 -1.95 -0.88 -0.56 0.18

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-30 2025-07-24 2024-10-30 2024-07-25 2024-05-02 2023-10-26 2023-07-27 2023-05-04 2022-10-27
acceptedDate 2025-10-30 07:00:11 2025-07-24 07:01:32 2025-02-27 07:01:11 2024-10-30 07:00:29 2024-07-25 07:05:37 2024-05-02 07:01:24 2024-02-22 07:05:37 2023-10-26 07:02:57 2023-07-27 07:02:15 2023-05-04 07:02:04 2023-02-23 07:05:47 2022-10-27 07:19:41 2022-02-24 06:57:10 2021-02-25 06:27:46
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 345M 150M 164M 185M 168M 454M 241M 155M 157M 186M 115M 244M 210M 246M
shortTermInvestments 691M 762M 796M 774M 786M 416M 670M 766M 784M 772M 854M 727M 729M 608M
cashAndShortTermInvestments 1 036M 912M 960M 964M 955M 870M 911M 921M 941M 958M 969M 970M 939M 854M
netReceivables 85M 129M 102M 67M 65M 87M 77M 88M 91M 99M 86M 105M 97M 100M
inventory 0 40M 35M 39M 40M 42M 38M 37M 33M 32M 29M 27M 24M 27M
otherCurrentAssets 79M 3M 2M 25M 37M 25M 2M 2M 516 000 676 000 20M 231 000 8M 14M
totalCurrentAssets 1 200M 1 083M 1 107M 1 095M 1 093M 1 003M 1 034M 1 048M 1 065M 1 089M 1 112M 1 102M 1 074M 999M
propertyPlantEquipmentNet 0 147M 120M 114M 107M 104M 98M 86M 79M 74M 69M 61M 54M 42M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 161M 16M 15M 12M 12M 15M 14M 12M 15M 11M 11M 11M 12M 11M
totalNonCurrentAssets 161M 163M 134M 127M 119M 119M 112M 98M 94M 85M 80M 72M 66M 53M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 361M 1 246M 1 241M 1 222M 1 212M 1 121M 1 146M 1 146M 1 159M 1 174M 1 192M 1 174M 1 139M 1 052M
accountPayables 119M 104M 105M 91M 90M 84M 94M 80M 83M 81M 85M 77M 73M 54M
shortTermDebt 561M 560M 558M 557M 0 76M 0 77M 68M 67M 0 64M 7M 6M
taxPayables 0 0 0 0 0 0 9M 0 0 0 9M 0 6M 5M
deferredRevenue 0 0 14M 0 -79M -76M 16M -80M 807 000 2M 18M 4M 18M 18M
otherCurrentLiabilities 96M 86M 0 86M 79M 76M 0 80M -807 000 -2M 0 -4M 169 000 61 000
totalCurrentLiabilities 776M 750M 756M 735M 169M 160M 179M 157M 150M 149M 159M 141M 143M 114M
longTermDebt 237M 140M 97M 118M 675M 595M 569M 590M 587M 586M 566M 580M 562M 430M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 807 000 2M 3M 4M 6M 12M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 5M 0 0 0 0 0
otherNonCurrentLiabilities 7M 6M 7M 8M 6M 7M 8M 5M 119 000 5M 5M 443M 5M 6M
totalNonCurrentLiabilities 244M 147M 124M 126M 681M 602M 605M 595M 593M 593M 592M 588M 586M 462M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 43M 43M 28M 21M 22M 26M 27M 22M 20M 20M 19M 15M 13M 14M
totalLiabilities 1 020M 896M 881M 861M 850M 762M 784M 753M 743M 742M 750M 729M 729M 575M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
retainedEarnings -1 266M -1 229M -1 154M -1 088M -1 058M -1 024M -986M -938M -889M -832M -778M -741M -686M -631M
accumulatedOtherComprehensiveIncomeLoss -6M -5M -6M -5M -4M -4M -5M -2M -2M -3M -2M -2M -3M -4M
othertotalStockholdersEquity 1 613M 1 583M 1 454M 1 423M 1 388M 1 334M 1 307M 1 266M 1 189M
totalStockholdersEquity 341M 349M 360M 361M 362M 359M 362M 394M 416M 432M 441M 445M 410M 477M
totalEquity 341M 349M 360M 361M 362M 359M 362M 394M 416M 432M 441M 445M 410M 477M
totalLiabilitiesAndStockholdersEquity 1 361M 1 246M 1 222M 1 212M 1 121M 1 146M 1 159M 1 174M 1 174M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 361M 1 246M 1 241M 1 222M 1 212M 1 121M 1 146M 1 146M 1 159M 1 174M 1 192M 1 174M 1 139M 1 052M
totalInvestments 691M 762M 796M 774M 786M 416M 670M 766M 784M 772M 854M 727M 729M 608M
totalDebt 798M 700M 683M 676M 675M 595M 596M 590M 587M 586M 584M 580M 582M 451M
netDebt 453M 551M 520M 490M 507M 141M 355M 435M 431M 400M 469M 336M 372M 205M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-22 2023-02-23 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 74M 61M 86M 94M 97M
otherReceivables 28M 16M 0 4M 4M
prepaids 7M 7M 6M 5M 4M
totalPayables 105M 94M 85M 78M 59M
otherPayables 0 0 0 6M 5M
accruedExpenses 71M 69M 56M 40M 30M
capitalLeaseObligationsCurrent 8M 0 0 0 0
capitalLeaseObligationsNonCurrent 20M 27M 19M 13M 14M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 520M 1 353M 1 222M 1 100M 1 111M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR NVCR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-30 2025-07-24 2024-10-30 2024-07-25 2024-05-02 2023-10-26 2023-07-27 2023-05-04 2022-10-27
acceptedDate 2025-10-30 07:00:11 2025-07-24 07:01:32 2025-02-27 07:01:11 2024-10-30 07:00:29 2024-07-25 07:05:37 2024-05-02 07:01:24 2024-02-22 07:05:37 2023-10-26 07:02:57 2023-07-27 07:02:15 2023-05-04 07:02:04 2023-02-23 07:05:47 2022-10-27 07:19:41 2022-02-24 06:57:10 2021-02-25 06:27:46
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -37M -40M -169M -31M -33M -39M -207M -49M -57M -53M -93M -27M -58M 20M
depreciationAndAmortization -3M 3M -14M 2M 3M 3M 11M 3M 3M 3M 11M 3M 10M 9M
deferredIncomeTax 0 0 0 0 0 0 0 2M -6M 0 0 0 4M -270 000
stockBasedCompensation 29M 26M 160M 31M 32M 34M 116M 26M 33M 39M 107M 26M 95M 76M
changeInWorkingCapital 30M -7M -4M 14M 3M -27M 30M 6M 2M -295 000 12M 20M 29M -9M
accountsReceivables 4M -10M -26M 5M -11M -3M 29M 3M 7M 15M 3M 12M 5M -30M
inventory 886 000 -629 000 3M 2M 2M -5M -9M -4M -1M -3M -4M 3M 2M -3M
accountsPayables 25M 2M 19M 7M 10M -18M 15M 6M 207 000 -10M 14M 5M 28M 25M
otherWorkingCapital 849 000 2M 384 000 -844 000 3M -591 000 -6M -5M -6M -1M -666 000 38 000 -6M -702 000
otherNonCashItems 1M 1M 932 000 -7M 31M -4M -22M -6M 3M -5M -6M 255 000 3M 3M
netCashProvidedByOperatingActivities 21M -16M -26M 10M -2M -32M -73M -19M -23M -17M 31M 22M 83M 99M
investmentsInPropertyPlantAndEquipment -6M -5M -43M -11M -11M -12M -27M -7M -7M -6M -21M -6M -24M -15M
acquisitionsNet 0 0 0 0 0 0 0 -25M 0 0 119M 0 121M 458M
purchasesOfInvestments -108M -379M -875M -169M -523M 0 -1 004M -251M -322M -238M -1 298M -503M -1 079M -608M
salesMaturitiesOfInvestments 185M 420M 778M 190M 160M 258M 1 215M 276M 315M 326M 1 179M 359M 958M 150M
otherInvestingActivites 0 0 0 -363M 258M 25M 0 0 0
netCashUsedForInvestingActivites 71M 36M 10M -374M 246M 17M -14M 82M -150M
debtRepayment 100M 0 0 84M 0 0 -3000 -7000 -7000
commonStockIssued 538 000 2M 100 000 2M 213 000 1M 3M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 251 000 100 000 1M 213 000 1M 5M 5M 4M
netCashUsedProvidedByFinancingActivities 101M 2M 100 000 87M 213 000 1M 8M 5M 4M
effectOfForexChangesOnCash -22 000 265 000 -174 000 87 000 -77 000 -56 000 131 000 -97 000 -13 000 41 000 -97 000 -107 000 -188 000 247 000
netChangeInCash 193M 23M -76M 21M -289M 215M 127M -982 000 -29M 71M -94M -124M -37M 67M
cashAtEndOfPeriod 345M 152M 166M 189M 168M 457M 243M 157M 157M 187M 116M 244M 210M 246M
cashAtBeginningOfPeriod 152M 129M 243M 168M 457M 243M 116M 157M 187M 116M 210M 368M 246M 179M
operatingCashFlow 21M -16M -26M 10M -2M -32M -73M -19M -23M -17M 31M 22M 83M 99M
capitalExpenditure -6M -5M -43M -11M -11M -12M -27M -7M -7M -6M -21M -6M -24M -15M
freeCashFlow 15M -21M -69M -307 000 -13M -43M -100M -27M -30M -23M 9M 17M 59M 84M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-22 2023-02-23 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 -119M -121M -458M
netCashProvidedByInvestingActivities -140M 184M -140M -145M -473M
netDebtIssuance 84M -10000 -28 000 -26 000 408M
longTermNetDebtIssuance 84M -10000 -28 000 -26 000 408M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 4M 4M 5M 5M 3M
netCommonStockIssuance 4M 4M 5M 5M 3M
commonStockIssuance 4M 4M 5M 5M 3M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 2M 11M 10M 21M 28M
netCashProvidedByFinancingActivities 90M 16M 15M 26M 440M
incomeTaxesPaid 23M 14M 5M 3M 0
interestPaid 8M 6000 41 000 101 000 0

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-07-25 ET (fiscal 2025 q2)
2025 q1
2025-04-24 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-07-25 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-07-23 11:00 ET
Novocure Reports Second Quarter 2026 Financial Results
2026-07-01 ET
Novocure to Report Second Quarter 2026 Financial Results
2026-06-30 ET
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
2026-06-18 ET
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
2026-04-30 ET
Novocure Reports First Quarter 2026 Financial Results
2026-04-01 ET
Novocure to Report First Quarter 2026 Financial Results
2026-03-26 ET
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
2026-03-02 ET
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
2026-02-27 ET
Novocure to Participate in 2026 Leerink Global Healthcare Conference
2026-02-26 ET
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
2026-02-24 ET
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
2026-02-11 22:54 ET
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
2026-01-12 ET
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
2025-12-22 ET
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-12-01 ET
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
2025-11-26 ET
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
2025-11-12 ET
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
2025-10-30 11:00 ET
Novocure Reports Third Quarter 2025 Financial Results
2025-10-15 ET
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
2025-10-01 ET
Novocure to Report Third Quarter 2025 Financial Results
2025-09-29 ET
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
2025-09-15 ET
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
2025-08-28 ET
Novocure Announces Upcoming Investor Events
2025-08-25 ET
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
2025-08-20 ET
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
2025-07-24 ET
Novocure Reports Second Quarter 2025 Financial Results
2025-07-01 ET
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
2025-06-30 ET
Novocure to Report Second Quarter 2025 Financial Results
2025-05-31 ET
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
2025-05-27 ET
Novocure Announces Upcoming Investor Events
2025-04-24 ET
Novocure Reports First Quarter 2025 Financial Results
2025-04-23 ET
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
2025-04-22 ET
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
2025-04-01 ET
Novocure to Report First Quarter 2025 Financial Results
2025-03-04 ET
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
2025-02-27 ET
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
2025-01-22 ET
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
2025-01-13 ET
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
2025-01-03 ET
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
2024-12-02 ET
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
2024-12-02 ET
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
2024-11-27 ET
Novocure to Participate in Upcoming Investor Conferences
2024-11-21 ET
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
2024-11-21 ET
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
2024-10-30 11:02 ET
Novocure Appoints Christoph Brackmann as Chief Financial Officer
2024-10-30 11:00 ET
Novocure Reports Third Quarter 2024 Financial Results
2024-10-01 11:00 ET
Novocure to Report Third Quarter 2024 Financial Results
2024-09-09 11:00 ET
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
2024-09-03 11:00 ET
Novocure Announces Planned CEO Transition
2024-08-28 11:00 ET
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
2024-08-14 11:00 ET
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
2024-07-25 11:00 ET
Novocure Reports Second Quarter 2024 Financial Results
2024-07-01 11:00 ET
Novocure to Report Second Quarter 2024 Financial Results
2024-06-03 12:00 ET
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
2024-05-23 21:05 ET
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
2024-05-02 11:01 ET
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
2024-05-02 11:01 ET
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
2024-05-02 11:00 ET
Novocure Reports First Quarter 2024 Financial Results
2024-04-24 14:45 ET
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
2024-04-05 11:00 ET
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
2024-04-01 11:00 ET
Novocure to Report First Quarter 2024 Financial Results
2024-03-27 11:00 ET
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
2024-03-11 11:00 ET
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
2024-02-22 12:00 ET
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
2024-01-18 12:00 ET
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
2024-01-09 12:00 ET
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
2024-01-08 12:00 ET
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
2024-01-04 21:05 ET
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
2023-12-27 12:00 ET
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
2023-11-28 12:30 ET
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
2023-11-21 12:00 ET
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
2023-11-10 13:00 ET
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
2023-10-26 11:00 ET
Novocure Reports Third Quarter 2023 Financial Results
2023-10-15 22:05 ET
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
2023-10-12 12:00 ET
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
2023-10-02 11:00 ET
Novocure to Report Third Quarter 2023 Financial Results
2023-09-29 21:00 ET
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
2023-09-08 20:01 ET
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
2023-08-29 22:31 ET
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
2023-08-28 11:00 ET
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
2023-08-25 11:00 ET
Novocure to Participate in Upcoming Investor Conferences
2023-08-15 13:00 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-08-15 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-08-10 13:00 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-08-10 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-08-07 13:00 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-08-07 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-08-03 13:00 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
2023-08-03 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
2023-07-31 13:00 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-07-31 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-07-27 13:00 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
2023-07-27 11:00 ET
Novocure Reports Second Quarter 2023 Financial Results
2023-07-27 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
2023-07-24 13:15 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-07-24 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-07-21 12:00 ET
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
2023-07-18 13:15 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-07-18 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-07-13 13:10 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-07-13 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-07-10 13:30 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
2023-07-10 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
2023-07-04 14:00 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
2023-07-04 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
2023-07-03 12:00 ET
Novocure to Report Second Quarter 2023 Financial Results
2023-06-29 13:00 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-06-29 ET
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-06-06 12:00 ET
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
2023-06-01 11:01 ET
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
2023-06-01 ET
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
2023-05-04 11:00 ET
Novocure Reports First Quarter 2023 Financial Results
2023-04-26 14:01 ET
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-04-14 12:27 ET
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
2023-04-03 12:00 ET
Novocure to Report First Quarter 2023 Financial Results
2023-03-29 11:30 ET
Kristin Stafford Joins Novocure Board of Directors
2023-03-16 11:30 ET
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
2023-03-01 12:01 ET
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
2023-03-01 12:00 ET
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
2023-02-23 12:00 ET
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
2023-02-23 12:00 ET
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
2023-02-15 12:00 ET
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
2023-01-19 12:30 ET
Novocure Announces Organizational Changes to Prepare for Future Growth
2023-01-09 12:00 ET
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
2023-01-05 12:00 ET
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
2022-12-27 13:00 ET
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
2022-11-29 13:00 ET
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
2022-11-23 13:00 ET
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
2022-11-17 13:00 ET
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
2022-11-15 13:00 ET
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
2022-11-11 13:00 ET
Novocure Secures CE Mark for New Array
2022-10-27 11:09 ET
Novocure Reports Third Quarter 2022 Financial Results
2022-10-21 22:03 ET
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
2022-10-20 13:21 ET
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
2022-10-20 13:16 ET
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
2022-10-03 12:00 ET
Novocure to Report Third Quarter 2022 Financial Results
2022-09-21 12:00 ET
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
2022-08-31 12:00 ET
Novocure to Participate in Upcoming Investor Conferences
2022-08-10 12:00 ET
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility
2022-07-28 11:00 ET
Novocure Reports Second Quarter 2022 Financial Results
2022-07-27 12:00 ET
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
2022-07-01 12:00 ET
Novocure to Report Second Quarter 2022 Financial Results
2022-06-21 12:00 ET
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
2022-06-03 12:00 ET
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
2022-05-26 12:00 ET
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
2022-04-28 11:00 ET
Novocure Reports First Quarter 2022 Financial Results
2022-04-19 20:45 ET
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
2022-04-08 11:00 ET
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
2022-04-01 11:30 ET
Novocure to Report First Quarter 2022 Financial Results
2022-03-24 20:00 ET
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
2022-03-23 12:00 ET
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
2022-02-28 12:00 ET
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
2022-02-24 21:24 ET
Novocure’s General Counsel Resigns After 10 Years of Service
2022-02-24 12:05 ET
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
2022-02-24 12:00 ET
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
2022-01-10 12:00 ET
Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update
2022-01-04 13:00 ET
Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
2021-12-07 21:11 ET
Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire
2021-12-06 13:00 ET
Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
2021-11-23 12:30 ET
Novocure to Participate in Two Upcoming Investor Conferences
2021-11-22 12:30 ET
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
2021-11-15 12:31 ET
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
2021-11-15 12:30 ET
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting
2021-10-28 10:30 ET
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
2021-10-28 10:30 ET
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
2021-10-21 11:30 ET
Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting
2021-10-04 11:30 ET
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
2021-10-04 11:30 ET
Novocure to Report Third Quarter 2021 Financial Results
2021-10-04 11:30 ET
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
2021-09-14 11:00 ET
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
2021-09-09 12:14 ET
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
2021-09-02 10:00 ET
Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
2021-09-01 11:50 ET
Novocure Appoints Bill Burke as Chief Human Resources Officer
2021-07-29 10:00 ET
Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update
2021-07-15 11:30 ET
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
2021-07-08 11:30 ET
Novocure to Report Second Quarter 2021 Financial Results
2021-07-01 11:15 ET
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
2021-06-16 11:30 ET
Novocure Initiates Usability Study for Flexible Torso Array
2021-05-25 11:30 ET
Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma
2021-05-18 11:30 ET
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
2021-04-29 10:00 ET
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update
2021-04-22 12:47 ET
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
2021-04-13 11:37 ET
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
2021-04-13 11:30 ET
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
2021-04-09 11:30 ET
Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
2021-04-01 10:00 ET
Novocure to Report First Quarter 2021 Financial Results
2021-02-25 11:00 ET
Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
2021-02-08 21:00 ET
Novocure Announces Addition to Its Board of Directors
2021-01-11 11:00 ET
Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update
2020-12-23 12:30 ET
Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference
2020-12-14 06:00 ET
Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
2020-12-10 12:30 ET
First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
2020-11-25 12:30 ET
Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference
2020-11-19 13:00 ET
Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting
2020-11-11 12:30 ET
Novocure Receives CE Mark for NovoTTF-100L™ System
2020-11-10 12:30 ET
Novocure Announces Agenda for Virtual Research and Development Day
2020-11-09 12:30 ET
Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks
2020-11-05 21:00 ET
Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement
2020-11-03 01:52 ET
Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement
2020-11-02 12:04 ET
Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes
2020-10-29 10:00 ET
Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research
2020-10-29 10:00 ET
Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update
2020-10-02 12:56 ET
Novocure to Report Third Quarter 2020 Financial Results
2020-09-29 11:30 ET
Novocure to Host Virtual Research & Development Day
2020-09-25 20:00 ET
Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community
2020-09-04 11:30 ET
Novocure to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
2020-08-13 12:30 ET
Novocure Announces Expansion of Its Executive Leadership Team
2020-07-30 10:00 ET
Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update
2020-07-28 11:30 ET
Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
2020-07-22 11:30 ET
First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays
2020-07-15 11:30 ET
Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
2020-07-08 11:30 ET
Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™
2020-07-07 11:30 ET
Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer

SEC forms

Show financial reports only

SEC form 8
2026-07-23 11:00 ET
Novocure published news for 2026 q2
SEC form 8
2026-07-23 11:00 ET
Novocure published news for 2026 q2
SEC form 10
2026-07-23 10:59 ET
Novocure published news for 2026 q2
SEC form 8
2026-06-30 11:00 ET
Novocure published news for 2026 q1
SEC form 8
2026-06-30 11:00 ET
Novocure published news for 2026 q1
SEC form 8
2026-06-18 11:00 ET
Novocure published news for 2026 q1
SEC form 8
2026-06-18 11:00 ET
Novocure published news for 2026 q1
SEC form 8
2026-04-30 11:01 ET
Novocure published news for 2026 q1
SEC form 8
2026-04-30 11:01 ET
Novocure published news for 2026 q1
SEC form 10
2026-04-30 11:01 ET
Novocure published news for 2026 q1
SEC form 8
2026-03-26 11:00 ET
Novocure published news for 2025 q4
SEC form 8
2026-03-26 11:00 ET
Novocure published news for 2025 q4
SEC form 10
2026-02-26 07:01 ET
Novocure published news for 2025 q4
SEC form 8
2026-02-26 07:01 ET
Novocure published news for 2025 q4
SEC form 8
2026-02-26 07:01 ET
Novocure reported for 2025 q4
SEC form 8
2026-02-11 22:24 ET
Novocure published news for 2025 q4
SEC form 8
2026-02-11 22:24 ET
Novocure published news for 2025 q4
SEC form 8
2026-01-12 12:00 ET
Novocure published news for 2025 q4
SEC form 8
2026-01-12 12:00 ET
Novocure published news for 2025 q4
SEC form 10
2025-10-30 11:00 ET
Novocure reported for 2025 q3
SEC form 8
2025-10-30 10:59 ET
Novocure published news for 2025 q3
SEC form 8
2025-10-30 10:59 ET
Novocure reported for 2025 q3
SEC form 8
2025-09-15 11:00 ET
Novocure published news for 2025 q2
SEC form 8
2025-09-15 11:00 ET
Novocure published news for 2025 q2
SEC form 8
2025-08-28 11:03 ET
Novocure published news for 2025 q2
SEC form 8
2025-07-24 11:02 ET
Novocure published news for 2025 q2
SEC form 8
2025-07-24 11:02 ET
Novocure reported for 2025 q2
SEC form 10
2025-07-24 11:01 ET
Novocure reported for 2025 q2
SEC form 8
2025-06-02 10:05 ET
Novocure published news for 2025 q1
SEC form 8
2025-06-02 10:05 ET
Novocure published news for 2025 q1
SEC form 8
2025-06-02 10:05 ET
Novocure published news for 2025 q1
SEC form 8
2025-06-02 10:05 ET
Novocure published news for 2025 q1
SEC form 8
2025-04-24 11:02 ET
Novocure published news for 2025 q1
SEC form 8
2025-04-24 11:02 ET
Novocure reported for 2025 q1
SEC form 10
2025-04-24 11:01 ET
Novocure published news for 2025 q1
SEC form 10
2025-04-24 00:00 ET
Novocure published news for 2025 q1
SEC form 8
2025-04-22 11:00 ET
Novocure published news for 2025 q1
SEC form 8
2025-04-22 11:00 ET
Novocure published news for 2025 q1
SEC form 8
2025-02-27 07:02 ET
Novocure published news for 2024 q4
SEC form 8
2025-02-27 07:02 ET
Novocure reported for 2024 q4
SEC form 10
2025-02-27 07:01 ET
Novocure published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Novocure published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Novocure published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Novocure published news for 2024 q4
SEC form 8
2024-10-30 07:02 ET
Novocure published news for 2024 q3
SEC form 8
2024-10-30 07:02 ET
Novocure published news for 2024 q3
SEC form 8
2024-10-30 07:02 ET
Novocure reported for 2024 q3
SEC form 8
2024-10-30 07:02 ET
Novocure published news for 2024 q3
SEC form 10
2024-10-30 07:00 ET
Novocure reported for 2024 q3
SEC form 10
2024-10-30 00:00 ET
Novocure reported for 2024 q3
SEC form 10
2024-07-25 07:05 ET
Novocure reported for 2024 q2
SEC form 8
2024-07-25 07:01 ET
Novocure published news for 2024 q2
SEC form 8
2024-07-25 07:01 ET
Novocure reported for 2024 q2
SEC form 10
2024-07-25 00:00 ET
Novocure published news for 2024 q2
SEC form 10
2024-05-02 07:01 ET
Novocure published news for 2024 q1
SEC form 8
2024-05-02 07:01 ET
Novocure published news for 2024 q1
SEC form 8
2024-05-02 07:01 ET
Novocure reported for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Novocure published news for 2024 q1
SEC form 8
2024-02-22 07:06 ET
Novocure published news for 2023 q4
SEC form 8
2024-02-22 07:06 ET
Novocure reported for 2023 q4
SEC form 10
2024-02-22 07:05 ET
Novocure published news for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Novocure published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Novocure published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Novocure published news for 2023 q4
SEC form 8
2023-10-26 07:03 ET
Novocure published news for 2023 q3
SEC form 10
2023-10-26 07:02 ET
Novocure reported for 2023 q3
SEC form 10
2023-10-26 00:00 ET
Novocure published news for 2023 q3
SEC form 6
2023-07-27 07:03 ET
Novocure published news for 2023 q2
SEC form 10
2023-07-27 07:02 ET
Novocure reported for 2023 q2
SEC form 10
2023-07-27 00:00 ET
Novocure published news for 2023 q2
SEC form 8
2023-07-27 00:00 ET
Novocure published news for 2023 q2
SEC form 6
2023-07-21 08:00 ET
Novocure published news for 2023 q2
SEC form 6
2023-06-08 16:12 ET
Novocure published news for 2023 q1
SEC form 6
2023-06-06 15:45 ET
Novocure published news for 2023 q1
SEC form 6
2023-06-06 12:18 ET
Novocure published news for 2023 q1
SEC form 6
2023-06-06 08:00 ET
Novocure published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Novocure published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Novocure published news for 2023 q1
SEC form 6
2023-03-29 07:31 ET
Novocure published news for 2022 q4
SEC form 10
2023-02-23 07:05 ET
Novocure reported for 2022 q4
SEC form 6
2023-02-23 07:04 ET
Novocure published news for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Novocure reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Novocure reported for 2022 q4
SEC form 6
2023-01-10 16:20 ET
Novocure published news for 2022 q4
SEC form 6
2023-01-09 07:02 ET
Novocure published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Novocure published news for 2022 q4
SEC form 6
2023-01-05 07:03 ET
Novocure published news for 2022 q4
SEC form 6
2022-11-04 08:35 ET
Novocure published news for 2022 q3
SEC form 6
2022-10-27 07:20 ET
Novocure published news for 2022 q3
SEC form 10
2022-10-27 07:19 ET
Novocure reported for 2022 q3
SEC form 10
2022-10-27 00:00 ET
Novocure reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Novocure reported for 2022 q3
SEC form 6
2022-07-28 07:03 ET
Novocure published news for 2022 q2
SEC form 10
2022-07-28 07:01 ET
Novocure reported for 2022 q2
SEC form 10
2022-07-28 00:00 ET
Novocure reported for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Novocure reported for 2022 q2
SEC form 6
2022-07-07 17:50 ET
Novocure published news for 2022 q2
SEC form 6
2022-06-10 16:15 ET
Novocure published news for 2022 q1
SEC form 6
2022-06-03 08:01 ET
Novocure published news for 2022 q1
SEC form 6
2022-05-26 08:04 ET
Novocure published news for 2022 q1
SEC form 6
2022-04-28 07:04 ET
Novocure published news for 2022 q1
SEC form 10
2022-04-28 07:03 ET
Novocure reported for 2022 q1
SEC form 10
2022-04-28 00:00 ET
Novocure reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Novocure reported for 2022 q1
SEC form 6
2022-04-25 16:14 ET
Novocure published news for 2022 q1
SEC form 6
2022-04-14 16:36 ET
Novocure published news for 2022 q1
SEC form 6
2022-04-14 16:00 ET
Novocure published news for 2022 q1
SEC form 6
2022-04-13 16:06 ET
Novocure published news for 2022 q1
SEC form 6
2022-04-07 16:07 ET
Novocure published news for 2022 q1
SEC form 6
2022-03-23 08:01 ET
Novocure published news for 2021 q4
SEC form 6
2022-03-09 16:53 ET
Novocure published news for 2021 q4
SEC form 6
2022-03-07 18:17 ET
Novocure published news for 2021 q4
SEC form 6
2022-02-24 07:00 ET
Novocure published news for 2021 q4
SEC form 10
2022-02-24 06:57 ET
Novocure published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Novocure published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Novocure published news for 2021 q4
SEC form 6
2022-01-12 17:39 ET
Novocure published news for 2021 q4
SEC form 6
2022-01-10 07:05 ET
Novocure published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Novocure published news for 2021 q4
SEC form 6
2022-01-05 16:52 ET
Novocure published news for 2021 q4
SEC form 6
2021-12-30 16:05 ET
Novocure published news for 2021 q3
SEC form 6
2021-12-07 16:01 ET
Novocure published news for 2021 q3
SEC form 10
2021-10-28 06:42 ET
Novocure published news for 2021 q3
SEC form 6
2021-10-28 06:37 ET
Novocure published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
Novocure published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Novocure published news for 2021 q3
SEC form 6
2021-09-03 16:34 ET
Novocure published news for 2021 q2
SEC form 6
2021-07-29 06:10 ET
Novocure published news for 2021 q2
SEC form 10
2021-07-29 06:09 ET
Novocure published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Novocure published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Novocure reported for 2021 q2
SEC form 6
2021-06-11 16:16 ET
Novocure published news for 2021 q1
SEC form 6
2021-04-29 06:08 ET
Novocure published news for 2021 q1
SEC form 10
2021-04-29 06:07 ET
Novocure published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
Novocure published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Novocure published news for 2021 q1
SEC form 6
2021-04-27 17:27 ET
Novocure published news for 2021 q1
SEC form 6
2021-04-13 09:17 ET
Novocure published news for 2021 q1
SEC form 6
2021-03-04 17:48 ET
Novocure published news for 2020 q4
SEC form 6
2021-02-25 06:30 ET
Novocure published news for 2020 q4
SEC form 10
2021-02-25 06:27 ET
Novocure published news for 2020 q4
SEC form 6
2021-02-12 19:11 ET
Novocure published news for 2020 q4
SEC form 6
2021-02-08 16:33 ET
Novocure published news for 2020 q4
SEC form 6
2021-02-01 16:19 ET
Novocure published news for 2020 q4
SEC form 6
2021-01-11 06:54 ET
Novocure published news for 2020 q4
SEC form 6
2020-11-09 07:49 ET
Novocure published news for 2020 q3
SEC form 6
2020-11-05 16:17 ET
Novocure published news for 2020 q3
SEC form 6
2020-11-03 16:23 ET
Novocure published news for 2020 q3
SEC form 6
2020-11-02 20:56 ET
Novocure published news for 2020 q3
SEC form 10
2020-10-29 06:17 ET
Novocure published news for 2020 q3
SEC form 6
2020-10-29 06:12 ET
Novocure published news for 2020 q3
SEC form 6
2020-10-02 16:25 ET
Novocure published news for 2020 q3
SEC form 6
2020-10-02 16:22 ET
Novocure published news for 2020 q3